NON-SMALL-CELL LUNG CARCINOMA
Clinical trials for NON-SMALL-CELL LUNG CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL-CELL LUNG CARCINOMA trials appear
Sign up with your email to follow new studies for NON-SMALL-CELL LUNG CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to reboot immune attack in Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new combination of two drugs (retifanlimab and ruxolitinib) in people with advanced lung or kidney cancer whose tumors grew despite prior immunotherapy. The main goal is to find the safest dose of ruxolitinib when given with a fixed dose of retifanlimab, and to…
Matched conditions: NON-SMALL-CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Apr 29, 2026 02:38 UTC
-
New hope for tough lung cancers: experimental drug takes on standard chemo
Disease control Recruiting nowThis study tests a new drug, PF-08046054, against the standard chemo docetaxel for people with advanced PD-L1 positive non-small cell lung cancer that has spread or can't be removed. About 680 adults whose cancer got worse after prior treatments will be randomly assigned to one o…
Matched conditions: NON-SMALL-CELL LUNG CARCINOMA
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC